Start clinical studies for V591
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 31 Jul 2020
- Due
- 30 Sep 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“V591 is currently in preclinical development and clinical studies are planned to start in the third quarter.”
What we found
Evidence strength A What the grades mean
Merck's filings confirm that V591 was in Phase 1 clinical development by November 2020, indicating that clinical studies had commenced within the third quarter of 2020 as planned.
-
A Merck & Co., Inc. 10-Q filed 2020-11-05
“the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development.” ✓ confirmed on the page
Market reaction: the shares moved -3.4% against the S&P 500 over the three sessions around the disclosure (4 Nov 2020 to 9 Nov 2020). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- V591 clinical studies
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Merck & Co., Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-MRK-003174 · Corrections policy